Barclays analyst Luke Sergott raised the firm’s price target on PacBio (PACB) to $2 from $1.50 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- PacBio price target raised to $2 from $1.50 at Piper Sandler
- PacBio price target raised to $2 from $1.80 at Stephens
- Pacific Biosciences’ Earnings Call: Mixed Results and Strategic Outlook
- Pacific Biosciences: Overcoming Short-Term Challenges with Strategic Innovations and Long-Term Growth Prospects